Can I Take Quercetin With Farxiga (Dapagliflozin)?

Why This Question Matters

Quercetin ranks among the most popular over-the-counter flavonoid supplements in the United States, with sales surging after 2020 due to interest in immune support. Farxiga (dapagliflozin) prescriptions have also grown rapidly since the FDA expanded its indications to include heart failure in 2020 and chronic kidney disease (CKD) in 2021 [1]. The overlap between these two populations is large: patients managing type 2 diabetes, cardiovascular risk, or CKD often explore dietary supplements as adjuncts. A supplement-drug interaction question deserves a specific, evidence-based answer rather than a blanket "ask your doctor."

The Core Concern

The worry centers on quercetin's ability to inhibit cytochrome P450 3A4 (CYP3A4), the same enzyme family that partially metabolizes dapagliflozin. If quercetin slows dapagliflozin clearance enough, circulating drug levels could rise, increasing the risk of hypoglycemia or volume depletion. The next sections break down whether that theoretical risk translates to a real clinical problem.

How Dapagliflozin Is Metabolized

Dapagliflozin is an SGLT2 inhibitor that blocks sodium-glucose co-transporter 2 in the proximal renal tubule, lowering blood glucose by promoting urinary glucose excretion. Its metabolic pathway is the starting point for evaluating any interaction.

UGT1A9: The Dominant Pathway

According to the Farxiga prescribing information filed with the FDA, dapagliflozin undergoes extensive glucuronidation primarily via UGT1A9 [2]. This single enzyme accounts for roughly 60 to 70% of the drug's total clearance. The resulting inactive metabolite, dapagliflozin 3-O-glucuronide, is renally excreted.

CYP3A4: A Minor Contributor

CYP3A4 contributes a smaller fraction of dapagliflozin metabolism, estimated at 10 to 15% based on mass-balance and in-vitro phenotyping studies described in the FDA clinical pharmacology review [2]. Because CYP3A4 handles only a minority of clearance, even moderate inhibition of this enzyme produces a limited change in overall drug exposure.

What the Formal Interaction Studies Show

AstraZeneca tested dapagliflozin co-administration with mefenamic acid (a strong UGT1A9 inhibitor) and with rifampin (a potent CYP3A4 inducer). Mefenamic acid increased dapagliflozin AUC by 51%, confirming UGT1A9's dominance [2]. Rifampin decreased AUC by 22%, confirming CYP3A4 plays a real but secondary role. No formal study has been conducted with a selective CYP3A4 inhibitor alone, but the rifampin data let us estimate the ceiling: if total CYP3A4 induction drops AUC by 22%, total CYP3A4 inhibition could raise it by a roughly proportional amount, likely in the 15 to 25% range for a strong inhibitor.

Quercetin as a CYP3A4 Inhibitor

Quercetin (3,3′,4′,5,7-pentahydroxyflavone) is found in onions, apples, berries, and tea. Supplement capsules typically deliver 500 to 1,000 mg per day, far above dietary intake of 10 to 50 mg/day.

In-Vitro Potency vs. Real-World Exposure

In-vitro studies consistently demonstrate that quercetin inhibits CYP3A4 with an IC50 in the low-micromolar range (approximately 1 to 10 µM depending on the substrate used) [3]. That sounds potent. The problem is oral bioavailability. A pharmacokinetic study published in the European Journal of Clinical Pharmacology found that quercetin's oral bioavailability in humans is only 2 to 5%, with peak plasma concentrations after a 500 mg dose reaching roughly 0.3 to 0.75 µM [4]. Those concentrations sit at or below the lower end of the in-vitro IC50 range, meaning systemic CYP3A4 inhibition at standard supplement doses is weak.

Intestinal vs. Hepatic Inhibition

Quercetin concentrations in the gut lumen and enterocyte are far higher than in plasma. A 2019 review in Molecular Nutrition & Food Research noted that intestinal CYP3A4 inhibition by flavonoids can reduce first-pass metabolism of co-administered drugs absorbed in the same region [5]. Dapagliflozin is rapidly and almost completely absorbed (oral bioavailability ~78%), so the window for intestinal interaction exists but is brief. Separating doses by two hours largely eliminates this intestinal overlap.

Estimating the Actual Interaction Magnitude

Putting the pharmacokinetic pieces together produces a practical risk estimate.

Quantitative Prediction

If quercetin at 500 mg achieves weak systemic CYP3A4 inhibition (perhaps 20 to 30% enzyme occupancy at best), and CYP3A4 handles only ~10 to 15% of dapagliflozin clearance, the net increase in dapagliflozin AUC from systemic inhibition alone would be:

0.15 (CYP3A4 fraction) × 0.25 (degree of inhibition) = ~3.75% AUC increase.

Even doubling the inhibition estimate to 50% enzyme occupancy only yields a ~7.5% AUC increase. For context, the FDA typically considers AUC changes <25% clinically insignificant for drugs with wide therapeutic indices [6]. Dapagliflozin has a relatively flat dose-response curve between 5 mg and 10 mg, and doses up to 50 mg were tested in early trials without dose-limiting toxicity [2].

Intestinal Component

Adding the intestinal CYP3A4 inhibition effect might push the total AUC change toward 10 to 15%, still well under the threshold of concern. This calculation aligns with the absence of adverse event reports linking the combination.

Pharmacodynamic Considerations

Beyond the enzyme-level interaction, quercetin and dapagliflozin share some overlapping biological effects worth understanding.

Additive Blood-Glucose Lowering

Quercetin has shown modest glucose-lowering properties in preclinical models and in a small number of human studies. A 2017 randomized controlled trial (N=72) in women with polycystic ovary syndrome found that quercetin 1,000 mg/day for 12 weeks reduced fasting glucose by 0.3 mmol/L compared with placebo [7]. That effect is mild, but it could add to dapagliflozin's glucose-lowering action in patients with tight glycemic control, increasing the chance of hypoglycemia. The DAPA-HF trial (N=4,744) documented a symptomatic hypoglycemia rate of only 0.2% in patients without diabetes on dapagliflozin 10 mg [8]. The additive risk from quercetin remains small.

Anti-Inflammatory Overlap

Both quercetin and dapagliflozin reduce markers of systemic inflammation. Dapagliflozin lowered hsCRP by 0.41 mg/L in the DECLARE-TIMI 58 trial (N=17,160) [9]. Quercetin's anti-inflammatory activity, mediated through NF-kB pathway inhibition, is well-characterized in vitro [3]. Whether this overlap is beneficial or harmful in vivo has not been studied in any controlled trial. It is not a reason to avoid the combination, but it is a reason to track inflammatory markers if your clinician orders them.

Antihistamine Effects

Quercetin stabilizes mast cells and inhibits histamine release, which is one reason it is marketed for allergy support [3]. Dapagliflozin has no known antihistamine activity. There is no pharmacodynamic conflict here, but patients using quercetin for allergies should be aware that its antihistamine effect may mask early symptoms of a urinary tract infection (dysuria, frequency), which SGLT2 inhibitors can predispose to [2]. Report new urinary symptoms to your prescriber promptly.

Monitoring Recommendations

A structured monitoring approach reduces residual risk to near zero.

Baseline and Ongoing Labs

Before adding quercetin to a Farxiga regimen, confirm the following are current (within the last 90 days): fasting blood glucose or HbA1c, basic metabolic panel including eGFR and serum potassium, and a urinalysis. The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guideline recommends eGFR monitoring every 3 months for patients on SGLT2 inhibitors with CKD [10].

Symptom Tracking

Watch for signs of volume depletion (dizziness on standing, reduced urine output, thirst) during the first two weeks after adding quercetin. These symptoms would suggest a clinically meaningful increase in dapagliflozin exposure, though the pharmacokinetic analysis above predicts this is unlikely.

When to Stop Quercetin

Discontinue quercetin and contact your prescriber if you experience recurrent hypoglycemia (blood glucose <70 mg/dL on home monitoring), new genital mycotic infection (a known SGLT2 inhibitor side effect that could theoretically worsen with higher drug levels), or any symptoms of diabetic ketoacidosis (nausea, abdominal pain, rapid breathing) even if blood glucose appears normal.

Dose-Separation Strategy

Timing your doses to minimize intestinal overlap is the simplest risk-reduction step.

The Two-Hour Rule

Take dapagliflozin with breakfast, as recommended in the Farxiga prescribing information [2]. Take quercetin at least two hours later (mid-morning or with lunch). This spacing allows dapagliflozin to clear the upper small intestine, where most absorption occurs, before quercetin arrives to inhibit local CYP3A4. "Separating a supplement from a drug by at least two hours is a standard precaution when intestinal enzyme inhibition is the primary concern," according to the Natural Medicines Comprehensive Database interaction monograph methodology [11].

If You Forget to Separate

A single instance of co-ingestion is not dangerous. The predicted AUC increase even with simultaneous dosing is modest. Simply resume the staggered schedule the next day. Do not skip your Farxiga dose.

What the Guidelines and Databases Say

No major clinical practice guideline (ADA, KDIGO, ACC/AHA) specifically addresses quercetin co-administration with SGLT2 inhibitors. The interaction databases provide the closest formal assessment.

Natural Medicines Database Rating

The Natural Medicines Comprehensive Database, maintained by the Therapeutic Research Center, classifies flavonoid-CYP3A4 substrate interactions as "moderate" theoretical risk with a "fair" evidence level [11]. It does not list a specific dapagliflozin-quercetin monograph but captures the class-level concern.

FDA FAERS Search

A search of the FDA Adverse Event Reporting System (FAERS) for dapagliflozin co-reported with "quercetin" returns zero cases as of Q1 2026 [12]. Absence of reports does not prove safety, but combined with the pharmacokinetic analysis, it supports a low-risk classification.

Special Populations

Patients With CKD (eGFR 25 to 60 mL/min/1.73 m²)

Dapagliflozin clearance is reduced in CKD because glucuronidation capacity decreases with declining renal function. The DAPA-CKD trial (N=4,304) still showed a favorable risk-benefit profile at eGFR as low as 25 [13]. Adding quercetin in this population warrants tighter monitoring (monthly eGFR for the first three months) because any incremental AUC increase stacks on top of already-elevated drug levels.

Older Adults (Age 65+)

Dapagliflozin AUC is approximately 13% higher in adults over 70 compared with younger patients, per the FDA label [2]. The combination with quercetin remains acceptable, but volume-depletion monitoring is especially important because older adults have reduced thirst perception and lower baseline intravascular volume.

Patients on Strong CYP3A4 Inhibitors

If you already take a strong CYP3A4 inhibitor (ketoconazole, itraconazole, clarithromycin, ritonavir), adding quercetin creates a second source of CYP3A4 inhibition. The combined effect on dapagliflozin is still limited by UGT1A9's dominance, but discuss this "stacking" scenario with your prescriber. A 2020 pharmacokinetic modeling study in Clinical Pharmacology & Therapeutics demonstrated that dual CYP3A4 inhibition rarely produces additive effects when the primary drug is not predominantly CYP3A4-cleared [14].

Bottom Line for Patients Already Taking Both

If you are currently taking quercetin with Farxiga and have experienced no hypoglycemia, volume depletion symptoms, or unusual lab shifts, the evidence strongly suggests you can continue. Inform your prescribing clinician at your next visit, separate doses by two hours if you are not already doing so, and maintain standard SGLT2-inhibitor monitoring (HbA1c every 3 months, annual eGFR, periodic urinalysis). Quercetin at doses up to 1,000 mg/day carries a predicted dapagliflozin AUC increase of <15%, which falls below the threshold for clinical dose adjustment per FDA bioequivalence standards [6].